Giustina A, Boni E, Romanelli G, Grassi V, Giustina G
Department of Internal Medicine, University of Brescia, Italy.
Am J Cardiol. 1995 May 15;75(15):1042-7. doi: 10.1016/s0002-9149(99)80721-8.
We studied 10 adult patients with active acromegaly (4 men and 6 women, mean age 55 +/- 5 years and mean body mass index 27.9 +/- 1.1 kg/m2). Control values for the echocardiographic and exercise studies were obtained from 10 normal subjects matched for sex and age (5 men and 5 women, age 51.1 +/- 3.7 years and body mass index 25.3 +/- 1 kg/m2). Each patient underwent: (1) blood sampling for growth hormone (GH) assay every 3 hours; (2) a 2-dimensional, guided M-mode echocardiographic study; and (3) a cycloergometric exercise test at baseline and after treatment with a portable pump infusing octreotide, 500 micrograms/24 hours subcutaneously. All patients had left ventricular hypertrophy. Systolic function indexes did not significantly differ among normal subjects, whereas baseline Doppler studies showed abnormalities in left ventricular diastolic filling in acromegalic patients. At anaerobic threshold and at maximal exercise, acromegalic subjects sustained a significantly (p < 0.05) decreased workload (54 +/- 23 vs 94 +/- 11 and 87 +/- 37 vs 152 +/- 15 W) compared with control subjects. After octreotide, baseline heart rate (79 +/- 7 vs 87 +/- 8 beats/min, p < 0.05) and serum GH levels significantly decreased compared with levels before administration of octreotide. Systolic and diastolic functional indexes at rest significantly improved after octrotide in acromegalic patients. Both at anaerobic threshold and at maximal exercise, workload and oxygen consumption were significantly increased after octretide administration. Exercise capacity at anaerobic threshold was not significantly different in acromegalic subjects after octreotide when compared with normal subjects.(ABSTRACT TRUNCATED AT 250 WORDS)
我们研究了10例活动性肢端肥大症成年患者(4例男性和6例女性,平均年龄55±5岁,平均体重指数27.9±1.1kg/m²)。超声心动图和运动研究的对照值取自10名年龄和性别匹配的正常受试者(5例男性和5例女性,年龄51.1±3.7岁,体重指数25.3±1kg/m²)。每位患者均接受:(1)每3小时采集一次血液样本用于生长激素(GH)检测;(2)二维引导M型超声心动图检查;(3)在基线时以及使用便携式泵皮下注射奥曲肽500μg/24小时治疗后进行症状限制性运动试验。所有患者均有左心室肥厚。正常受试者的收缩功能指标无显著差异,而基线多普勒研究显示肢端肥大症患者左心室舒张期充盈存在异常。在无氧阈值和最大运动时,与对照受试者相比,肢端肥大症患者的工作量显著降低(分别为54±23 vs 94±11以及87±37 vs 152±15W,p<0.05)。使用奥曲肽后,与用药前相比,基线心率(79±7 vs 87±8次/分钟,p<0.05)和血清GH水平显著降低。肢端肥大症患者在使用奥曲肽后静息时的收缩和舒张功能指标显著改善。在无氧阈值和最大运动时,使用奥曲肽后工作量和耗氧量均显著增加。与正常受试者相比,肢端肥大症患者在使用奥曲肽后的无氧阈值运动能力无显著差异。(摘要截短至250字)